Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COXFA4 | O00483 | 1/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 13/20 | 0.42 |
| ▸ | ODC1 | P11926 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13071765 | 0.94 | COXFA4 (0.68) | COXFA4HSP90AA1HIF1AODC1ALDH1A1 | |
| SCHEMBL12315603 | 0.90 | COXFA4 (0.57) | COXFA4HSP90AA1HIF1AALDH1A1CYP3A4 | |
| SCHEMBL14098877 | 0.83 | COXFA4 (0.89) | COXFA4HSP90AA1HIF1AODC1EPAS1 | |
| SCHEMBL12315467 | 0.77 | COXFA4 (0.46) | COXFA4HIF1AALDH1A1CYP3A4HPGD | |
| SCHEMBL13071290 | 0.77 | COXFA4 (0.46) | COXFA4HIF1AALDH1A1CYP3A4HPGD | |
| SCHEMBL14666188 | 0.76 | HSP90AA1 (0.54) | COXFA4HSP90AA1HIF1AALDH1A1CYP3A4 | |
| SCHEMBL14139185 | 0.76 | COXFA4 (1.00) | COXFA4HSP90AA1HIF1AODC1EPAS1 | |
| SCHEMBL12315566 | 0.75 | COXFA4 (0.68) | COXFA4HSP90AA1HIF1AODC1 | |
| SCHEMBL12315602 | 0.72 | COXFA4 (0.84) | COXFA4HSP90AA1HIF1AEPAS1 | |
| SCHEMBL14098881 | 0.71 | COXFA4 (0.74) | COXFA4HSP90AA1HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | COXFA4 2119/4885HSP90AA1 1970/4885HIF1A 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.